

Eye On The Market
Michael Cembalest
Join Michael Cembalest as he explores a wide variety of investment topics, including the economy, policy and markets.
Episodes
Mentioned books

Jul 29, 2020 • 12min
COVID Research: Charts of the Week
US infection plateau; Liz Cheney; Hong Kong’s reaction to a mini second wave; Phase I Oxford vaccine antibody response; US spending and hospitalization trends; an update on infections in US hotspots and Latin America; Government march-in rights and herd immunity.

Jul 7, 2020 • 12min
Blinded by Science: the US recovery, virus surge and scientific trust gap
US recovery marches on; why deaths are diverging from sharply rising infections; the American scientific trust gap vs the rest of the world; energy paper client Q&A.

Jun 29, 2020 • 17min
Stargazing: Tenth Annual Eye on the Market Energy Paper
While COVID temporarily reduced global CO2 emissions to 2006 levels, a faster and broader renewable energy transition will be needed to result in more permanent reductions. This year’s topics include decarbonization of steel; the amount of energy storage, reforestation and carbon sequestration required to make an impact; and the financial, political and environmental risks to US energy independence.

May 26, 2020 • 16min
Zoom Room
In this week’s Eye on the Market, we review topics from our recent client Zoom calls. Topics include: risk of inflation, second waves of infection, the effectiveness of lockdowns and Biden’s taxation and spending agenda.

May 11, 2020 • 14min
Ready or Not: The US prepares to reopen
An update on the COVID-19 crisis as the US prepares to reopen despite having one of the highest infection rates in the world. Additional topics: monoclonal antibodies and anti-viral trials; the growing gap between markets and the economy; S&P 500 earnings haves and have-nots; regional equity performance (Europe loses again) and leveraged loans at a time of rising bankruptcies.

Apr 17, 2020 • 8min
Covid-19 Update
Michael discusses updates on the Covid19 crisis, including the potential path of decline in US infection rates, the impact of the new fed facilities, the difference between virus and serology testing, and the new vaccine efforts underway.

Mar 29, 2020 • 11min
Man vs Nature
Michael discusses what the government can and can not fix during a pandemic. In particular, he walks through US high frequency manufacturing and consumer data, the Fed measures, the studies on Chloroquine, and infection outbreak prediction models.

Mar 23, 2020 • 13min
COVID-19 update: infection rates, medical research and equity markets
Michael discusses the coronavirus latest infection rates by country and latitude, anti-viral and vaccine efforts, and what equity markets are pricing in.

Mar 5, 2020 • 21min
Berning Man
An update on the Democratic Primary. Confounding almost every forecast we saw last week, Senator Biden appears to have emerged from Super Tuesday with a sizeable delegate lead. Why might the night have turned out so differently from what was expected just a few days ago? This week's note includes some charts and exhibits to think about.

Feb 6, 2020 • 17min
Millions and Trillions
Answers to questions on the coronavirus, US megacap stocks, the cost of Democratic Healthcare plans, the Iowa caucus and the problem with the student loan system.


